BACKGROUND: Overexpression of estrogen receptors in malignant pleural mesothelioma has shown an independent relation with a better prognosis of survival, and the use of selective estrogen receptor beta (ERβ) agonists increases the susceptibility to antitumor treatment. METHODS: This was a retrospective single center study that analyzed the response of malignant pleural mesothelioma with an expression of ERβ to first-line chemotherapy. The study included patients with pleural mesothelioma pathologically confirmed between 2013 and 2016 at the National Institute for Respiratory Disease (INER), who underwent an immunohistochemistry assay for ERβ (mouse monoclonal antibody PPG5/10). The primary endpoint was the response to chemotherapy based on RECIST 1.1 according to the ERβ expression; secondary outcomes were the overall survival (OS) and progression-free survival (PFS). RESULTS: We included 22 patients, regarding the expression of ERβ, 17 (77.2%) patients had high or moderate degree, while 5 (22.7%) had low degree or null expression. The response to treatment as by RECIST 1.1, 12 (54.5%) had partial response, 5 (22.7%) had stable disease, and 3 (13.6%) had progression. None of the patients had a complete response. Of those who had a partial response, 9 (75%) had a high or moderate degree of ERβ expression in tumor cells, and 3 (25%) had a low or null degree of expression. CONCLUSIONS: High and moderate expression of ERβ group with advanced clinical stage malignant pleural mesothelioma was associated with a tendency of higher OS and better response to chemotherapy treatment resulting in longer PFS although statistical significance was not achieved.
BACKGROUND: Overexpression of estrogen receptors in malignant pleural mesothelioma has shown an independent relation with a better prognosis of survival, and the use of selective estrogen receptor beta (ERβ) agonists increases the susceptibility to antitumor treatment. METHODS: This was a retrospective single center study that analyzed the response of malignant pleural mesothelioma with an expression of ERβ to first-line chemotherapy. The study included patients with pleural mesothelioma pathologically confirmed between 2013 and 2016 at the National Institute for Respiratory Disease (INER), who underwent an immunohistochemistry assay for ERβ (mouse monoclonal antibody PPG5/10). The primary endpoint was the response to chemotherapy based on RECIST 1.1 according to the ERβ expression; secondary outcomes were the overall survival (OS) and progression-free survival (PFS). RESULTS: We included 22 patients, regarding the expression of ERβ, 17 (77.2%) patients had high or moderate degree, while 5 (22.7%) had low degree or null expression. The response to treatment as by RECIST 1.1, 12 (54.5%) had partial response, 5 (22.7%) had stable disease, and 3 (13.6%) had progression. None of the patients had a complete response. Of those who had a partial response, 9 (75%) had a high or moderate degree of ERβ expression in tumor cells, and 3 (25%) had a low or null degree of expression. CONCLUSIONS: High and moderate expression of ERβ group with advanced clinical stage malignant pleural mesothelioma was associated with a tendency of higher OS and better response to chemotherapy treatment resulting in longer PFS although statistical significance was not achieved.
Authors: Guadalupe Aguilar-Madrid; Cuauhtémoc A Juárez-Pérez; Steven Markowitz; Mauricio Hernández-Avila; Francisco Raúl Sanchez Roman; Juan Humberto Vázquez Grameix Journal: Int J Occup Environ Health Date: 2003 Jul-Sep
Authors: Astrid Haegens; Trisha F Barrett; Joanna Gell; Arti Shukla; Maximilian Macpherson; Pamela Vacek; Matthew E Poynter; Kelly J Butnor; Yvonne M Janssen-Heininger; Chad Steele; Brooke T Mossman Journal: J Immunol Date: 2007-02-01 Impact factor: 5.422
Authors: Terence C Chua; Peng Yao; Javed Akther; Lawrence Young; Shisan Bao; Ushma Samaraweera; Tristan D Yan; David L Morris Journal: Pathol Oncol Res Date: 2009-04-29 Impact factor: 3.201
Authors: Jeffrey A Tsou; Janice S Galler; Anil Wali; Wei Ye; Kimberly D Siegmund; Susan Groshen; Peter W Laird; Sally Turla; Michael N Koss; Harvey I Pass; Ite A Laird-Offringa Journal: Lung Cancer Date: 2007-07-30 Impact factor: 5.705
Authors: Mary Jane Teta; Pamela J Mink; Edmund Lau; Bonnielin K Sceurman; Edward D Foster Journal: Eur J Cancer Prev Date: 2008-11 Impact factor: 2.497
Authors: P T K Saunders; M R Millar; K Williams; S Macpherson; C Bayne; C O'Sullivan; T J Anderson; N P Groome; W R Miller Journal: Br J Cancer Date: 2002-01-21 Impact factor: 7.640
Authors: Abeer M Shaaban; Andrew R Green; Suchita Karthik; Yalda Alizadeh; Thomas A Hughes; Lynn Harkins; Ian O Ellis; John F Robertson; Emma C Paish; Philippa T K Saunders; Nigel P Groome; Valerie Speirs Journal: Clin Cancer Res Date: 2008-08-15 Impact factor: 12.531